文献速递白血病

MAPK通路激活介导慢性淋巴细胞白血病对PI3K抑制剂耐药

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2021-01-01

该研究对28例接受PI3K抑制剂治疗的多重复发慢性淋巴细胞白血病患者进行纵向全外显子测序,发现无应答者中60%基线存在MAP2K1、BRAF、KRAS激活突变,且PI3Kδ抑制未能抑制ERK磷酸化,而MEK抑制剂可恢复ERK抑制,提示MAPK/ERK激活是耐药关键机制。

要点

  • 无应答CLL患者中60%基线存在MAP2K1、BRAF或KRAS激活突变。
  • PI3Kδ抑制在无应答者中未能抑制ERK磷酸化,无论是否携带突变。
  • MEK抑制剂可恢复ERK抑制,支持PI3Kδ联合ERK抑制剂治疗策略。

核心结论

  • MAPK/ERK通路激活在CLL对PI3Kδ抑制剂耐药中起关键作用。

研究设计与样本

  • 对28例入组PI3K抑制剂试验的多重复发CLL患者进行纵向全外显子测序。

主要发现

  • 无应答者中60%基线存在MAP2K1、BRAF和KRAS基因激活突变。
  • PI3Kδ抑制在无应答CLL细胞中未能抑制ERK磷酸化,无论是否携带突变。
  • MEK抑制剂处理可恢复ERK抑制。
  • 体外过表达MAP2K1突变体导致基础及诱导性pERK升高和对idelalisib耐药。

临床怎么用

  • PI3Kδ抑制剂耐药CLL可考虑联合ERK抑制剂治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inhibitors of Bruton tyrosine kinase (BTK) and phosphatidylinositol 3-kinase δ (PI3Kδ) that target the B-cell receptor (BCR) signaling pathway have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Mutations associated with resistance to BTK inhibitors have been identified, but limited data are available on mechanisms of resistance to PI3Kδ inhibitors. Here we present findings from longitudinal whole-exome sequencing of cells from patients with multiply relapsed CLL (N = 28) enrolled in trials of PI3K inhibitors. The nonresponder subgroup was characterized by baseline activating mutations in MAP2K1, BRAF, and KRAS genes in 60% of patients. PI3Kδ inhibition failed to inhibit ERK phosphorylation (pERK) in nonresponder CLL cells with and without mutations, whereas treatment with a MEK inhibitor rescued ERK inhibition. Overexpression of MAP2K1 mutants in vitro led to increased basal and inducible pERK and resistance to idelalisib. These data demonstrate that MAPK/ERK activation plays a key role in resistance to PI3Kδ inhibitors in CLL and provide a rationale for therapy with a combination of PI3Kδ and ERK inhibitors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Murali I, Kasar S, Naeem A, et al. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. Blood. 2021. PMID: 33684943. doi:10.1182/blood.2020006765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。